Published in AIDS on November 30, 2007
Health needs of HIV-infected women in the United States: insights from the women living positive survey. AIDS Patient Care STDS (2011) 1.30
Atazanavir pharmacokinetics with and without tenofovir during pregnancy. J Acquir Immune Defic Syndr (2011) 1.24
Pharmacokinetics and therapeutic drug monitoring of antiretrovirals in pregnant women. Br J Clin Pharmacol (2008) 1.04
Safety of protease inhibitors in HIV-infected pregnant women. HIV AIDS (Auckl) (2013) 0.85
Atazanavir: its role in HIV treatment. Expert Rev Anti Infect Ther (2008) 0.85
Pregnancy-Associated Changes in Pharmacokinetics: A Systematic Review. PLoS Med (2016) 0.83
Placental transfer of darunavir in an ex vivo human cotyledon perfusion model. Antimicrob Agents Chemother (2014) 0.82
Pharmacokinetics of an increased atazanavir dose with and without tenofovir during the third trimester of pregnancy. J Acquir Immune Defic Syndr (2013) 0.82
Clinical and pharmacogenetic factors affecting neonatal bilirubinemia following atazanavir treatment of mothers during pregnancy. AIDS Res Hum Retroviruses (2013) 0.81
Protecting the fetus against HIV infection: a systematic review of placental transfer of antiretrovirals. Clin Pharmacokinet (2014) 0.80
German-Austrian recommendations for HIV1-therapy in pregnancy and in HIV1-exposed newborn, update 2008. Eur J Med Res (2009) 0.78
Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3. N Engl J Med (2007) 5.83
Similar adherence rates favor different virologic outcomes for patients treated with nonnucleoside analogues or protease inhibitors. Clin Infect Dis (2004) 3.95
Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomised, phase 2b trial. Lancet Infect Dis (2011) 3.58
Delayed graft function in kidney transplantation. Lancet (2004) 3.06
Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection. N Engl J Med (2013) 3.05
Effect of adherence to HAART on virologic outcome and on the selection of resistance-conferring mutations in NNRTI- or PI-treated patients. HIV Clin Trials (2007) 2.43
Ameliorating hypertension and insulin resistance in subjects at increased cardiovascular risk: effects of acetyl-L-carnitine therapy. Hypertension (2009) 2.20
Risk of developing specific AIDS-defining illnesses in patients coinfected with HIV and hepatitis C virus with or without liver cirrhosis. Clin Infect Dis (2009) 1.95
One-pill once-a-day HAART: a simplification strategy that improves adherence and quality of life of HIV-infected subjects. Patient Prefer Adherence (2010) 1.84
Health care-associated native valve endocarditis: importance of non-nosocomial acquisition. Ann Intern Med (2009) 1.76
Regulatory T cells and T cell depletion: role of immunosuppressive drugs. J Am Soc Nephrol (2007) 1.75
Extending the platinum-free interval with a non-platinum therapy in platinum-sensitive recurrent ovarian cancer. Results from the SOCRATES Retrospective Study. Oncology (2007) 1.70
Factors associated with the failure of HIV-positive persons to return for scheduled medical visits. HIV Clin Trials (2002) 1.65
How to fully protect the kidney in a severe model of progressive nephropathy: a multidrug approach. J Am Soc Nephrol (2002) 1.52
African sleeping sickness in tourists returning from Tanzania: the first 2 Italian cases from a small outbreak among European travelers. Clin Infect Dis (2001) 1.49
Simpler regimens may enhance adherence to antiretrovirals in HIV-infected patients. HIV Clin Trials (2002) 1.48
Hepatitis C infection and chronic renal diseases. Clin J Am Soc Nephrol (2009) 1.45
Effects of combined ezetimibe and simvastatin therapy as compared with simvastatin alone in patients with type 2 diabetes: a prospective randomized double-blind clinical trial. Diabetes Care (2010) 1.44
In renal transplantation blood cyclosporine levels soon after surgery act as a major determinant of rejection: insights from the MY.S.S. trial. Kidney Int (2004) 1.42
New times for an old disease: intracranial mass lesions caused by Mycobacterium tuberculosis in 5 HIV-negative African immigrants. Clin Infect Dis (2004) 1.40
Renal transplantation: can we reduce calcineurin inhibitor/stop steroids? Evidence based on protocol biopsy findings. J Am Soc Nephrol (2003) 1.40
Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin as first-line treatment for patients with ovarian cancer: the MITO-2 randomized phase III trial. J Clin Oncol (2011) 1.36
Consensus report on therapeutic drug monitoring of mycophenolic acid in solid organ transplantation. Clin J Am Soc Nephrol (2010) 1.33
The relationship between the initiation of antimicrobial therapy and the incidence of stroke in infective endocarditis: an analysis from the ICE Prospective Cohort Study (ICE-PCS). Am Heart J (2007) 1.26
Candida infective endocarditis: report of 15 cases from a prospective multicenter study. Medicine (Baltimore) (2009) 1.24
Alkhurma hemorrhagic fever in travelers returning from Egypt, 2010. Emerg Infect Dis (2010) 1.22
Age at infection affects the long-term outcome of transfusion-associated chronic hepatitis C. Blood (2002) 1.22
Propionibacterium endocarditis: a case series from the International Collaboration on Endocarditis Merged Database and Prospective Cohort Study. Scand J Infect Dis (2007) 1.21
Hepatitis B virus co-infection in human immunodeficiency virus-infected subjects. AIDS Rev (2002) 1.18
Sirolimus versus cyclosporine therapy increases circulating regulatory T cells, but does not protect renal transplant patients given alemtuzumab induction from chronic allograft injury. Transplantation (2007) 1.18
Effect of acetate-free biofiltration and bicarbonate hemodialysis on neutrophil activation. Am J Kidney Dis (2002) 1.16
CD4+ T lymphocyte recovery in individuals with type 1 human immunodeficiency virus infection. Clin Infect Dis (2010) 1.15
Increasing clinical virulence in two decades of the Italian HIV epidemic. PLoS Pathog (2009) 1.10
Performance of genotypic tropism testing on proviral DNA in clinical practice: results from the DIVA study group. New Microbiol (2012) 1.10
Prevalence of hypovitaminosis D and factors associated with vitamin D deficiency and morbidity among HIV-infected patients enrolled in a large Italian cohort. J Acquir Immune Defic Syndr (2011) 1.09
C-440T/T-331C polymorphisms in the UGT1A9 gene affect the pharmacokinetics of mycophenolic acid in kidney transplantation. Pharmacogenomics (2007) 1.07
Performance of genotypic tropism testing in clinical practice using the enhanced sensitivity version of Trofile as reference assay: results from the OSCAR Study Group. New Microbiol (2010) 1.06
Transvaginal endoscopic cholecystectomy in human beings: preliminary results. J Laparoendosc Adv Surg Tech A (2008) 1.05
Epidemiological network analysis in HIV-1 B infected patients diagnosed in Italy between 2000 and 2008. Infect Genet Evol (2011) 1.04
Once-a-day therapy for HIV infection: a controlled, randomized study in antiretroviral-naive HIV-1-infected patients. Antivir Ther (2003) 1.03
Effect of combining ACE inhibitor and statin in severe experimental nephropathy. Kidney Int (2002) 1.03
Rules-based HIV-1 genotypic resistance interpretation systems predict 8 week and 24 week virological antiretroviral treatment outcome and benefit from drug potency weighting. J Antimicrob Chemother (2009) 1.01
Mycophenolate, clinical pharmacokinetics, formulations, and methods for assessing drug exposure. Transplant Rev (Orlando) (2010) 1.00
Antiretroviral therapy in HIV-infected patients: a proposal to assess the economic value of the single-tablet regimen. Clinicoecon Outcomes Res (2013) 1.00
The aggravating mechanisms of aldosterone on kidney fibrosis. J Am Soc Nephrol (2008) 0.99
CD4+ T cell depletion, immune activation and increased production of regulatory T cells in the thymus of HIV-infected individuals. PLoS One (2010) 0.96
Virological response to salvage therapy in HIV-infected persons carrying the reverse transcriptase K65R mutation. Antivir Ther (2007) 0.94
Effect of prolonged discontinuation of successful antiretroviral therapy on CD4 T cells: a controlled, prospective trial. AIDS (2004) 0.94
Expression levels of p53 and p73 isoforms in stage I and stage III ovarian cancer. Eur J Cancer (2007) 0.94
Nitric oxide donor and non steroidal anti inflammatory drugs as a therapy for muscular dystrophies: evidence from a safety study with pilot efficacy measures in adult dystrophic patients. Pharmacol Res (2012) 0.94
CD4 cell-guided scheduled treatment interruptions in HIV-infected patients with sustained immunologic response to HAART. AIDS (2009) 0.93
Co-administration of ibuprofen and nitric oxide is an effective experimental therapy for muscular dystrophy, with immediate applicability to humans. Br J Pharmacol (2010) 0.92
A dual acting compound releasing nitric oxide (NO) and ibuprofen, NCX 320, shows significant therapeutic effects in a mouse model of muscular dystrophy. Pharmacol Res (2011) 0.91
Perceptions and patterns of use of generic drugs among Italian family pediatricians: first round results of a web survey. Health Policy (2012) 0.91
Italian guidelines for the use of antiretroviral agents and the diagnostic-clinical management of HIV-1 infected persons. New Microbiol (2011) 0.91
Primary stage I-IIE non-Hodgkin's lymphoma of uterine cervix and upper vagina: evidence for a conservative approach in a study on three patients. Gynecol Oncol (2005) 0.91
Low body weight in females is a risk factor for increased tenofovir exposure and drug-related adverse events. PLoS One (2013) 0.90
Diverse effects of increasing lisinopril doses on lipid abnormalities in chronic nephropathies. Circulation (2003) 0.90
MicroGen: a MIAME compliant web system for microarray experiment information and workflow management. BMC Bioinformatics (2005) 0.90
Single-Tablet Regimens in HIV Therapy. Infect Dis Ther (2014) 0.90
Duration of first-line antiretroviral therapy with tenofovir and emtricitabine combined with atazanavir/ritonavir, efavirenz or lopinavir/ritonavir in the Italian ARCA cohort. J Antimicrob Chemother (2012) 0.89
Population pharmacokinetics of mycophenolic acid : a comparison between enteric-coated mycophenolate sodium and mycophenolate mofetil in renal transplant recipients. Clin Pharmacokinet (2008) 0.89
Exploratory analysis for the evaluation of lopinavir/ritonavir-versus efavirenz-based HAART regimens in antiretroviral-naive HIV-positive patients: results from the Italian MASTER Cohort. J Antimicrob Chemother (2005) 0.88
Neoadjuvant chemotherapy and surgical considerations in ovarian cancer. Curr Opin Obstet Gynecol (2003) 0.88
Rilpivirine, a non-nucleoside reverse transcriptase inhibitor for the treatment of HIV infection. Curr Opin Investig Drugs (2008) 0.87
Effects of structured treatment interruptions on metabolic, anthropometric, immunologic, and quality of life outcomes in HIV-positive adults on HAART. Curr HIV Res (2007) 0.86
Predictors of AIDS-defining events among advanced naïve patients after HAART. HIV Clin Trials (2007) 0.86
Reasons for discontinuation of nevirapine-containing HAART: results from an unselected population of a large clinical cohort. J Antimicrob Chemother (2007) 0.86
Genotype resistance profiles in patients failing an NNRTI-containing regimen, and modifications after stopping NNRTI therapy. J Clin Lab Anal (2002) 0.86
Patient-reported outcomes and low-level residual HIV-RNA in adolescents perinatally infected with HIV-1 after switching to one-pill fixed-dose regimen. AIDS Care (2011) 0.86
Is the interruption of antiretroviral treatment during pregnancy an additional major risk factor for mother-to-child transmission of HIV type 1? Clin Infect Dis (2009) 0.86
Images in cardiovascular medicine. Bacterial pericarditis due to Providencia stuartii: an atypical case of relapsing pericarditis. Circulation (2010) 0.85
A randomized phase 3 study comparing once-daily elvitegravir with twice-daily raltegravir in treatment-experienced subjects with HIV-1 infection: 96-week results. J Acquir Immune Defic Syndr (2013) 0.85
Evaluation of the MicroSeq 500 16S rDNA-based gene sequencing for the diagnosis of culture-negative bacterial meningitis. New Microbiol (2008) 0.84
Mitochondrial changes during D-drug-containing once-daily therapy in HIV-positive treatment-naive patients. Antivir Ther (2010) 0.84
Systemic Inflammation-Based Biomarkers and Survival in HIV-Positive Subject With Solid Cancer in an Italian Multicenter Study. J Acquir Immune Defic Syndr (2015) 0.84
Kidney injury molecule 1: in search of biomarkers of chronic tubulointerstitial damage and disease progression. Am J Kidney Dis (2009) 0.84
Simultaneous determination of everolimus and cyclosporine concentrations by HPLC with ultraviolet detection. Clin Chim Acta (2005) 0.84
Back to the ring: knocking-out headache. Neurol Sci (2011) 0.83
Intraperitoneal chemotherapy in advanced epithelial ovarian cancer: a survey. Arch Gynecol Obstet (2014) 0.83
Virological effectiveness and CD4+ T-cell increase over early and late courses in HIV infected patients on antiretroviral therapy: focus on HCV and anchor class received. AIDS Res Ther (2012) 0.82
Once-a-day HAART: dream or reality? HIV Clin Trials (2003) 0.82
Treatment of primary effusion lymphoma with highly active antiviral therapy in the setting of HIV infection. AIDS (2008) 0.82
Ibuprofen-arginine generates nitric oxide and has enhanced anti-inflammatory effects. Pharmacol Res (2009) 0.82
Improving the prediction of virological response to tipranavir: the development and validation of a tipranavir-weighted mutation score. Antivir Ther (2010) 0.82
Recurrent granulosa cell tumors (GCTs) of the ovary: a MITO-9 retrospective study. Gynecol Oncol (2013) 0.81